Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.64 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29681825 | 1.00 | MAP2K1 (0.64) | MAP2K1MAP2K2MEN1KMT2AMAPK1 | |
| SCHEMBL31354762 | 0.87 | MAP2K1 (0.67) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL28884401 | 0.84 | MAP2K1 (0.88) | MAP2K1MAP2K2MAPK1IDO1 | |
| SCHEMBL30022894 | 0.84 | MAP2K1 (0.88) | MAP2K1MAP2K2MAPK1IDO1 | |
| SCHEMBL4860159 | 0.81 | MAP2K1 (0.75) | MAP2K1MAP2K2IDO1AURKATNFRSF1A | |
| SCHEMBL1340491 | 0.79 | MAP2K1 (0.57) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL6185889 | 0.79 | MAP2K1 (0.67) | MAP2K1MAP2K2MAPK1IDO1AURKA | |
| SCHEMBL24539659 | 0.79 | MAP2K1 (0.49) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL29681681 | 0.79 | MAP2K1 (0.49) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL188505 | 0.78 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083844-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2024-03-14 | — | — | US | disclosed |
| CN-117083265-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022133040-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083844-A1 | KINASE INHIBITORS AND USES THEREOF | MINK1, PTK2, PLK4 | MAP2K1 267/4885MAP2K2 257/4885MEN1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.